Bold claim: a gentler yet highly effective combination outperforms the conventional chemotherapy standard for newly diagnosed AML. In a recent trial, patients treated with atezolizumab? just kidding—the actual regimen, azacitidine plus venetoclax ( aza-ven ), showed notably better outcomes than standard intensive induction chemotherapy. This aza-ven approach, already the go-to option for older adults who cannot tolerate aggressive chemo, is now tested head-to-head against induction chemotherapy in a younger, fitness-appropriate cohort.
The study achieved its primary goal: event-free survival (EFS) improved with aza-ven. It also yielded higher overall response rates and greater composite complete responses compared with intensive induction in patients eligible for aggressive treatment. Additionally, more patients who responded could proceed to transplant, early mortality was reduced, overall quality of life during the initial treatment phase improved, and hospital time decreased.
Quote from the lead author, Amir Fathi, MD: the data support using aza-ven in this population, extending potential benefits to adverse- and intermediate-risk groups without FLT3 mutations. He notes that other patient subsets might also gain from this approach, but would require dedicated studies.
Medical context: AML is a bone marrow cancer characterized by an excess of abnormal white blood cells that undermines healthy blood cell production. While stem cell transplantation can cure AML, it’s not suitable for everyone, so initial treatments focus on reducing cancer burden before a transplant. The traditional frontline regimen—intensive induction chemotherapy with cytarabine and anthracyclines—forces many patients into roughly a month of hospitalization and carries substantial risks of infection, bleeding, and other complications.
Azacitidine is a longstanding injectable chemotherapy agent used especially in older patients with AML. Venetoclax, an oral drug, targets the BCL-2 protein to halt cancer cell survival. Together, they’re generally well tolerated and increasingly manageable in outpatient settings over time.
In this trial, 172 adults were randomized to aza-ven or standard intensive chemotherapy. The aza-ven group demonstrated a clear advantage in EFS, defined as time to relapse, disease progression, treatment-change due to refractoriness, or death. With a median follow-up just under 22 months, median EFS exceeded 14 months for aza-ven versus a little over six months for induction chemotherapy. The benefit persisted after adjustment for other factors, and at one year, 53% in the aza-ven arm were event-free compared with 36% in the control arm.
Eligibility nuances: the trial excluded patients with certain genetic profiles, including core-binding factor fusions, FLT3 mutations, or NPM1 mutations (unless the patient was aged 60 or older). Consequently, the study’s population skewed toward intermediate-to-high-risk AML, though all participants were fit enough for intensive induction therapy.
Dr. Fathi emphasizes that the findings support aza-ven use in this specific population, particularly for those without FLT3 mutations. He acknowledges that other patient groups could benefit as well, but their benefits must be established through targeted research.
Key outcomes:
- Overall response: 88% in the aza-ven arm vs 62% in the induction arm
- Composite complete response: 78% vs 54%
- Transplantation: 61% vs 40%
- Early death (within 60 days): 0% vs 5%
- ICU admission during initial hospitalization: 0% in aza-ven vs 10% in induction
- Quality of life and symptom burden: better scores and fewer depressive symptoms with aza-ven at two weeks
Safety profile: the rate of grade 3/4 treatment-related adverse events was similar between groups. Hospitalization was shorter for aza-ven patients. Overall, aza-ven was associated with fewer early deaths and less severe early treatment burdens.
Next steps: ongoing analyses will compare costs, infection rates, and other factors that influence treatment choices for this patient population. Researchers will also evaluate measurable residual disease to refine prognostic and predictive information across study arms and to determine the optimal aza-ven treatment duration before transplant.
Trial logistics: the study was investigator-initiated, funded and supplied by Genentech and AbbVie Inc. The research team plans additional presentations and analyses to further inform clinical decisions.
Source note: the principal investigator, Amir Fathi, MD, of Mass General Brigham Cancer Institute and Harvard Medical School, presented these findings on Sunday, December 7, 2025, at 3:45 p.m. ET during the Plenary Scientific Session at the Orange County Convention Center.
What this means for patients and clinicians: these results suggest that aza-ven can offer stronger disease control, higher likelihood of proceeding to transplant, and an improved early treatment experience for a substantial subset of AML patients who are otherwise eligible for intensive chemotherapy. Yet debates remain about which patients benefit most and how to balance cost, accessibility, and long-term outcomes. Do you think this shifts the standard of care for fit AML patients, or should these findings be validated in broader populations first? Share your thoughts in the comments.
%2c_analyze_by_microscope-Jarun_Ontakrai_8864dd9cfb3b4dff9a913aede7a7c915-620x480.jpg)
